Cadila Healthcare Ltd has announced that its Zydus Cadila unit has received four products approval from the U.S. Food and Drug Administration.

The group has got nod to promote Pravastatin sodium tabs USP 10, 20, 40 and 80 mg, and tentative authorizations for Escitalopram Oxalate tabs 5, 10 and 20 mg, Losartan potassium and Hydrochlorothiazide tabs 50mg/12.5 mg and 100mg/25mg and Anastrazole Tablets 1 mg.

Escitalopram is used for the treatment of depression, whereas anastrazole is a hormone therapy for breast cancer.

Previously, the USFDS approved the sale of cholesterol fighter pravastatin sodium tabs and tentatively approved losartan potassium-hydrochlorthiazide tablets to lower high blood pressure.

The US market of Pravastatin Sodium Tablets was estimated at around $1.9 billion during the last year (2007), whilst the branded sales of Escitalopram Oxalate Tablets stood at $3 billion.

osartan Potassium and Hydrochlorothiazide tablets was estimated at USD 785 million and that of Anastrazole tablets was estimated at USD 813 million in 2007.

Losartan Potassium and Hydrochlorthiazide Tablets, an anti-hypertensive, was estimated at $785 million and that of Anastrazole Tablets, a hormone therapy to treat breast cancer is estimated was estimated at $813, the company has said.

At 1.50 pm, the shares of the company gained 1.0% to trade at Rs 308.50 on the Bombay Stock Exchange (BSE).